Louisiana has become the first state in the United States to classify two FDA-approved abortion drugs as controlled substances — a historic and deeply controversial move that doctors say will harm patients well beyond the abortion debate.
Governor Jeff Landry, a Republican, signed the bill into law on Friday. It places mifepristone and misoprostol — both approved by the FDA more than two decades ago — on Louisiana's controlled substances list alongside drugs like Xanax and Valium as Schedule IV drugs.
What the Louisiana Abortion Pills Law Does
The new law reclassifies mifepristone and misoprostol as Schedule IV controlled dangerous substances under Louisiana's Uniform Controlled Dangerous Substances Law. This is notable because neither drug is considered addictive by the medical community, and controlled substance classifications are typically reserved for drugs with proven abuse or dependency potential.
Under the law, doctors who wish to prescribe either medication must obtain a special permit. Patients will be required to have their prescriptions logged in a state database — one that law enforcement can access without a warrant. Critics say this arrangement raises serious concerns about patient privacy and the potential for criminal investigation of both doctors and patients.
Possession of mifepristone or misoprostol without a valid prescription can result in a felony charge carrying up to five years in prison and fines of up to $5,000. Distribution or possession with intent to distribute carries penalties of up to 10 years in prison and fines reaching $15,000. Pregnant women who possess the drugs for their own use are exempt from these penalties.
Broader Impact on Medical Care
Opponents of the law argue that the harm extends far beyond abortion. Both mifepristone and misoprostol are widely used in standard obstetric and gynecological care — for inducing labor, managing miscarriages, and preventing life-threatening ulcer-related bleeding. Restricting access to these medications creates serious risks for patients with urgent medical needs unrelated to abortion.
"It creates more onus, more chaos and confusion for the people who use this medication," said Kirsten Moore of the American Sexual Health Association and head of the Expanding Medication Abortion Access (EMMA) Project. "Its intent is to put mifepristone and misoprostol back in the medicine chest."
The American College of Medical Toxicology has stated that neither drug meets the definition of a controlled substance, and that classifying them as such is "not consistent with decades of scientific evidence."
Political Context
The legislation passed Louisiana's Republican-dominated House and Senate, and is designed in part to make it harder for individuals to obtain these pills from out of state or via the internet without a prescription. The move comes against the backdrop of ongoing national litigation over access to medication abortion, and returns abortion restrictions to the political agenda in a presidential election year.
Louisiana already bans most abortions. This law tightens those restrictions further while drawing national attention to the question of how far states can go in regulating FDA-approved medications.
